Vaccinex

Vaccinex ROA

The Return on Assets (ROA) of Vaccinex (VCNX) as of Nov 22, 2026 is -292.38 %. In the previous year, Return on Assets (ROA) was -717.80 % — a change of -59.27% (higher).

ROA

-292.38 %

YoY

-59.27%

Last updated:

In 2025, Vaccinex's return on assets (ROA) was -292.38 %, a -59.27% increase from the -717.80 % ROA in the previous year.

The Vaccinex ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-134.00 USD
Jan 1, 2019
-695.37 USD
Jan 1, 2020
-246.55 USD
Jan 1, 2021
-227.37 USD
Jan 1, 2022
-247.24 USD
Jan 1, 2023
-557.73 USD
Jan 1, 2024
-717.80 USD
Jan 1, 2025
-292.38 USD
The Vaccinex ROA history
YEARROAYoY
-292.38 %-59.27%
-717.80 %+28.70%
-557.73 %+125.58%
-247.24 %+8.74%
-227.37 %-7.78%
-246.55 %-64.54%
-695.37 %+418.93%
-134.00 %-60.10%
-335.82 %-31.55%
-490.61 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vaccinex Stock analysis

What does Vaccinex do? Vaccinex, Inc. develops targeted biotherapeutics for serious diseases such as cancer, neurodegenerative diseases, and autoimmune disorders. The company generates revenue through its SEMA4D antibody platform, focusing on VX15 for non-small cell lung cancer, osteosarcoma, melanoma, and Huntington’s disease. It also utilizes the ActiveMAb antibody discovery platform for developing VX5, which is in preclinical stages for multiple sclerosis and other autoimmune disorders. Vaccinex targets healthcare providers and pharmaceutical companies seeking novel treatments for unmet medical needs. Vaccinex's lead product candidate VX15 is developed using the SEMA4D platform to address non-small cell lung cancer, osteosarcoma, and melanoma. The company's ActiveMAb platform supports the creation of high-affinity human monoclonal antibodies, which are used in VX5 for multiple sclerosis treatment. These platforms enable Vaccinex to offer innovative solutions for diseases with limited therapeutic options. The company's focus on clinical-stage development means it currently does not generate revenue from product sales but relies on partnerships and potential future licensing agreements. Vaccinex's target segments include patients with non-small cell lung cancer, osteosarcoma, melanoma, Huntington’s disease, and multiple sclerosis, as well as pharmaceutical companies interested in acquiring or co-developing its platforms and product candidates. Vaccinex is one of the most popular companies on Eulerpool.

ROA Details

Understanding Vaccinex's Return on Assets (ROA)

Vaccinex's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Vaccinex's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Vaccinex's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Vaccinex’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Vaccinex stock

Return on Assets (ROA) of Vaccinex is -292.38 % in 2025.

Return on Assets (ROA) of Vaccinex changed from -717.80 % to -292.38 %, representing a -59.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Vaccinex since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Vaccinex with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Vaccinex

All Key Metrics — Vaccinex